Increasing access to medicines: Better care for more patients

Promoted content

Due to austerity measures and weak growth, our ageing populations and rising healthcare costs driven by new, expensive treatments, European healthcare faces unprecedented and growing pressures.

To successfully address this challenge policymakers must recognise the fundamental importance and potential of generic, biosimilar and value-added medicines in ensuring the sustainability of European healthcare and enabling more patients to access treatment (up to 100% more).

Policymakers should face the reality that the cost of inaction, in terms of undermining access to health, is unacceptably high.

Learn more at

Download PDF  

Subscribe to our newsletters